Solrex close to open offer trigger for Orchid

Solrex Pharmaceuticals, believed to be a Ranbaxy Laboratories-promoted company, has reportedly increased its stake in Chennai-based drug major Orchid Chemicals and Pharmaceuticals to 14.72 per cent "" just short of the 15 per cent mark that will trigger an open offer to acquire the cephalosporin drug major.

A TV channel reported today that Solrex has increased its stake in Orchid to 14.72 per cent in bulk share purchase deals on Friday. The channel also said other Ranbaxy promoter group companies might have also garnered shares in Orchid.

According to the National Stock Exchange (NSE) data available yesterday, Solrex had 12.84 per cent stake in Orchid, all acquired in different deals after March this year.

The development could not be confirmed with the stock exchanges and Orchid. An official spokesperson of Orchid said he was yet to get details of the share purchase data of Orchid. Ranbaxy officials declined to comment on the developments.

A few days ago, Malvinder Mohan Singh, the managing director and chief executive officer of Ranbaxy, had stated that the company was against any hostile takeovers.

Orchid maintained that Solrex was understood to be an investment unit of Ranbaxy and the share purchases by Solrex were value picking rather than a takeover attempt.

Orchid's Chairman and Managing Director K Raghavendra Rao has only 15.9 per cent stake in Orchid. In case of an open offer, one option before him is to utilise the warrants worth about Rs 50 lakh, which can be converted into a 7 per cent stake. This would increase Rao's stake close to 23 per cent, said sources.

Reportedly, the Orchid management is in talks with financial institutions to convert the warrants and to rope in strategic investors to thwart the takeover attempts.

"We are observing the developments, but have not taken any decision on conversion of the warrants," said the company spokesperson. Both Raghavendra Rao and Deputy Managing Director C B Rao are still away in Japan, as a part of the opening of a subsidiary of Orchid in Japan.

Life Insurance Corporation of India and United India Insurance Company hold 7.8 per cent and 2.48 per cent, respectively in Orchid.

Other large institutional investors in the company include Gazal Industrial Holdings (8.48 per cent), Macquarie Bank (5.13 per cent), Harpline (4.54 per cent) and Fidelity Trustee Company (2.66 per cent).